Related Experiment Videos

Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a

Sharon Cresci1, Gerald W Dorn, Philip G Jones

  • 1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Journal of the American College of Cardiology
|June 19, 2012
PubMed

Insights

Genetic variations in the adrenergic pathway impact survival differently for Caucasian and African American patients after acute coronary syndrome (ACS) when treated with beta-blockers (BB). This race-specific effect highlights potential for personalized medicine in cardiovascular care.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Clinical Outcomes Research

Background:

  • Beta-blocker (BB) therapy post-acute coronary syndrome (ACS) is a quality metric, but its effectiveness varies across racial groups.
  • Racial disparities in ACS outcomes are a significant concern in U.S. healthcare.
  • Genetic factors, particularly in the adrenergic pathway, may influence cardiovascular disease treatment responses.

Purpose of the Study:

  • To investigate whether genetic polymorphisms in the adrenergic pathway are associated with survival in ACS patients treated with BB.
  • To determine if these genetic associations differ by race (Caucasian vs. African American).

Main Methods:

  • Prospective cohort study of 2,673 ACS patients (2,072 Caucasian, 601 African-American) treated with BB.
  • Genotyping for polymorphisms in ADRB1, ADRB2, ADRA2C, and GRK5.
  • Two-year follow-up for mortality, analyzed using proportional hazards regression stratified by race.

Main Results:

  • Overall 2-year mortality was 7.5% for Caucasians and 16.7% for African Americans.
  • In Caucasians, ADRA2C deletion carriers showed significantly lower mortality (HR 0.46).
  • In African Americans, the ADRB2 16R allele was linked to significantly higher mortality (HR 2.10-2.65).

Conclusions:

  • Adrenergic pathway genetic variants are associated with post-ACS mortality in a race-specific manner among patients on BB therapy.
  • These findings suggest that genetic background influences BB efficacy differently across racial groups.
  • Understanding these mechanisms may lead to tailored BB therapies to improve ACS outcomes in diverse populations.
Abstract

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...